Yumanity Therapeutics Shares Drop 29% After Results for Parkinson's Treatment Trial
November 10 2021 - 9:45AM
Dow Jones News
By Chris Wack
Yumanity Therapeutics Inc. shares fell 29% to $6.05 after the
company reported that its lead product candidate, YTX-7739 achieved
its primary endpoints in a Phase 1b clinical trial in patients with
mild-to-moderate Parkinson's disease.
Yumanity said YTX-7739 was generally well tolerated, and results
were consistent with earlier studies in healthy volunteers and
preclinical models. YTX-7739 was shown to inhibit its primary
target, stearoyl-CoA desaturase, an enzyme whose inhibition has
been closely linked to neuronal survival and improved motor
function in a Parkinson's disease model, the company said.
The company said that after 28 days of dosing there were no
statistically significant differences in clinical assessments or
most exploratory biomarkers. Quantitative electroencephalogram
assessments of the effect of YTX-7739 on brain activity were
completed in a subset of eight patients and demonstrated a
statistically significant change compared to baseline, suggestive
of a potential improvement in synaptic function.
The company said it expects to further validate the role of the
diagnostic marker in future clinical studies.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 10, 2021 10:30 ET (15:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024
